Ultragenyx (RARE) also reaffirmed its net cash used in operations guidance for 2025, which is expected to modestly increase compared to 2024 and its path to full year GAAP profitability in 2027.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- RARE Upcoming Earnings Report: What to Expect?
- Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome
- Ultragenyx announces first patient dosed in Aurora study
- Ultragenyx’s MPS VII Study: A Closer Look at Market Implications
- Ultragenyx’s Ongoing Study on UX111: A Potential Game-Changer for MPS IIIA Treatment